Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5660413 | 0.92 | HTR1A (0.59) | MGLLHTR1ADRD2PTGER1PTGER4 | |
| SCHEMBL9270709 | 0.85 | HTR1A (0.50) | MGLLHTR1AMAPTMAPK1TDP1 | |
| SCHEMBL24041895 | 0.84 | HTR1A (0.46) | MGLLHTR1ADRD2PTGER1PTGER4 | |
| SCHEMBL5250473 | 0.84 | HTR1A (0.54) | HTR1ADRD2ABCB1ABCG2 | |
| SCHEMBL6617663 | 0.84 | L3MBTL1 (0.53) | MGLLMAPTL3MBTL1 | |
| SCHEMBL4851116 | 0.84 | HTR1A (0.56) | MGLLHTR1ADRD2PTGER1PTGER4 | |
| SCHEMBL7215472 | 0.83 | MAPT (0.44) | MGLLMAPTL3MBTL1 | |
| SCHEMBL3169417 | 0.82 | L3MBTL1 (0.57) | MGLLPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL772767 | 0.81 | HTR1A (0.51) | HTR1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL24041898 | 0.80 | ABCB1 (0.64) | MGLLHTR1ADRD2ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| WO-2012075277-A2 | SYNTHETIC METHODS | NOVOMER, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075277-A2 | SYNTHETIC METHODS | NOVOMER, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| CN-102442941-A | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-101636386-A | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2010-01-27 | — | — | CN | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-0683781-B1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | METABASIS THERAPEUTICS INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-5731432-A | Inhibitors of adenosine monophosphate deaminase | GENSIA SICOR INC. (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0683781-A4 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE. | GENSIA PHARMA (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0683781-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA PHARMACEUTICALS, INC. (US) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018200-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | MGLL 3703/4885HTR1A 2025/4885DRD2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.